CHF114.34 pre-market: NOVN.SW Novartis AG (SIX) most active 22 Jan 2026, PE19.45
We start pre-market at CHF114.34 and Novartis AG (NOVN.SW) is among the most active names on the SIX this morning. Volume is 3,036,686.00 shares versus an average of 2,961,566.00, signalling above-normal trade interest. NOVN.SW stock trades at a PE of 19.45 with EPS 5.88, and an earnings release set for 04 Feb 2026. Our Meyka AI-powered market analysis flags momentum and fundamental drivers that matter to short-term traders and longer-term investors.
Price and market activity for NOVN.SW stock
NOVN.SW stock opened at CHF114.38 and trades between CHF113.70 and CHF114.70 today. Market cap is CHF219,394,690,886.00 and on-balance volume is elevated, with relative volume 1.03. Daily moves have been modest; the 52-week range is CHF81.10 to CHF116.78. The active volume profile shows institutional interest ahead of the company earnings on 2026-02-04.
Fundamentals and valuation of NOVN.SW stock
Novartis reports EPS 5.88 and a trailing PE of 19.45, which sits below many large healthcare peers on the SMI. Return on equity is 34.12% and free cash flow yield is 6.64%, supporting the company’s 3.06% dividend yield. Price/Book is 6.31 and debt/equity is 0.72, signalling moderate leverage. These ratios explain why investors weigh growth in Innovative Medicines against valuation compression in generics.
Technical snapshot and trading signals for NOVN.SW stock
Momentum indicators show NOVN.SW stock is overbought: RSI 74.23 and Stochastic %K 92.86. MACD sits at 2.11 with a signal line 1.59, supporting short-term bullish bias. Bollinger Bands middle is CHF108.81 and ATR is 1.69, suggesting limited daily volatility. Traders should monitor RSI and on-balance volume for signs of a pullback or continuation.
Sector context and comparative performance for NOVN.SW stock
The Healthcare sector is outperforming this quarter with a 3-month gain of 11.49%. Novartis compares favourably on ROE and margin metrics versus peers, while the sector average PE is higher. Sandoz legacy issues and Innovative Medicines growth drive mixed headlines, so sector momentum often lifts or weighs on NOVN.SW stock depending on drug approvals and generics news.
Analyst view, Meyka grade and price targets for NOVN.SW stock
Meyka AI rates NOVN.SW with a score out of 100: 74.97 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Independent analyst snapshots show a typical three-tier target band: conservative CHF100.00, base CHF120.00, and bull CHF140.00. The company’s payout ratio 54.32% and dividend per share 4.40 support income-focused allocations.
Risks and catalysts affecting NOVN.SW stock
Key catalysts include the upcoming earnings on 04 Feb 2026, pipeline readouts, and regulatory updates for key drugs. Risks include Sandoz margin pressure, patent expiries, and FX exposure. Short-term technical overbought signals raise the chance of a pullback near CHF116.78 (year high). Watch trading volume and news flow for sudden re-rating events.
Final Thoughts
Key takeaways: NOVN.SW stock opens pre-market at CHF114.34 with elevated volume 3,036,686.00, a PE of 19.45, and EPS 5.88. Meyka AI’s forecast model projects a five-year level near CHF123.85, implying an upside of 8.32% versus today’s price, while a one-year model sits near CHF100.53, implying downside of -12.08%. These model outputs highlight a risk-reward trade-off between near-term earnings volatility and longer-term recovery in pipeline and margin expansion. Traders prioritising momentum should monitor RSI and volume; longer-term investors should weigh valuation versus steady free cash flow and a 3.06% dividend yield. Remember, forecasts are model-based projections and not guarantees. For real-time trade signals and deeper metric views use Meyka AI’s platform and follow primary sources for updates MarketWatch coverage of NOVN and sector flows on Bloomberg sector note.
FAQs
What drives short-term moves in NOVN.SW stock?
Short-term moves in NOVN.SW stock track earnings, pipeline news and trading volume. Technicals like RSI 74.23 and on-balance volume matter for day traders. Upcoming earnings on 04 Feb 2026 often amplify volatility.
Is NOVN.SW stock a buy after recent gains?
NOVN.SW stock shows strong fundamentals and a Meyka AI grade B+ (BUY), but it is near overbought technicals. Consider valuation (PE 19.45) and your time horizon before adding exposure.
What price targets should investors watch for NOVN.SW stock?
Analyst bands and Meyka forecasts suggest a conservative target CHF100.00, base CHF120.00, and bull CHF140.00. Meyka AI’s five-year model points to CHF123.85, implying about 8.32% upside from CHF114.34.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
